(Q36418019)

14 August 2017

1 reference

title

Sertindole : a review of its use in schizophrenia (English)

1 reference

14 August 2017

0 references

1 reference

ChEBI release 2020-05-28

2

Gillian M Keating

1 reference

14 August 2017

David Murdoch

1

1 reference

14 August 2017

publication date

1 January 2006

1 reference

14 August 2017

number of pages

23

1 reference

inferred from page(s)

published in

CNS Drugs

1 reference

14 August 2017

volume

20

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

233-255

1 reference

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia

14 August 2017

cites work

1 reference

12 December 2020

The new and evolving pharmacotherapy of schizophrenia

1 reference

12 December 2020

Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers.

1 reference

12 December 2020

Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia

1 reference

12 December 2020

Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function

1 reference

12 December 2020

The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.

1 reference

12 December 2020

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

1 reference

12 December 2020

Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics

1 reference

12 December 2020

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy

1 reference

12 December 2020

Parametric PET imaging of 5HT2A receptor distribution with 18F-setoperone in the normal human neocortex.

1 reference

12 December 2020

Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance

1 reference

12 December 2020

Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic

1 reference

12 December 2020

A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia

1 reference

12 December 2020

Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation

1 reference

12 December 2020

Introduction to sertindole in clinical practice

1 reference

12 December 2020

Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studies

1 reference

12 December 2020

The acute effect of sertindole on brain 5-HT2, D2 and ?1 receptors (ex vivo radioreceptor binding studies)

1 reference

12 December 2020

Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.

1 reference

12 December 2020

Sertindole for schizophrenia

1 reference

12 December 2020

Sertindole and several antipsychotic drugs differentially inhibit the discriminative stimulus effects of amphetamine, LSD and St 587 in rats.

1 reference

12 December 2020

Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: Results of a phase III trial

1 reference

12 December 2020

Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment

1 reference

12 December 2020

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

1 reference

12 December 2020

Pharmacokinetics of sertindole in healthy young and elderly male and female subjects.

1 reference

12 December 2020

Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine

1 reference

12 December 2020

A review of the efficacy, tolerability and safety of sertindole in clinical trials

1 reference

12 December 2020

Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole

1 reference

12 December 2020

The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers

1 reference

12 December 2020

Lack of multiple dosing effect of sertindole on the pharmacokinetics of alprazolam in healthy volunteers

1 reference

12 December 2020

Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine

1 reference

12 December 2020

Sertindole: cardiac electrophysiological profile

1 reference

12 December 2020

A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs

1 reference

12 December 2020

Clinical observations of sertindole in 53 hospitalised patients with psychotic disorders

1 reference

12 December 2020

Lack of CYP3A inhibition effects of sertindole on terfenadine in healthy volunteers

1 reference

12 December 2020

Sertindole and dopamine D 2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123 I-IBZM SPECT study

1 reference

12 December 2020

Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys

1 reference

12 December 2020

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

1 reference

12 December 2020

Sertindole: a clinical efficacy profile

1 reference

12 December 2020

Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm.

1 reference

12 December 2020

QTc interval prolongation and antipsychotic drug treatments: focus on sertindole

1 reference

12 December 2020

A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

1 reference

12 December 2020

Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors

1 reference

12 December 2020

Olanzapine, sertindole and schizophrenia

1 reference

12 December 2020

In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole--a 123I IBZM single photon emission tomography (SPET) study

1 reference

12 December 2020

Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice.

1 reference

12 December 2020

Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs

1 reference

12 December 2020

Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed

1 reference

12 December 2020

Electrophysiological safety of sertindole in dogs with normal and remodeled hearts

1 reference

12 December 2020

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

12 December 2020

Treatment-resistant schizophrenia: reviewing the options and identifying the way forward.

1 reference

12 December 2020

Sertindole improves both the positive and negative symptoms of schizophrenia: Results of a phase III trial

1 reference

12 December 2020

10.2165/00023210-200620030-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

14 August 2017

1009088009

0 references

1 reference